摘要
目的:系统评价二甲双胍联合标准一线方案治疗晚期非小细胞肺癌的疗效,为非小细胞肺癌的临床合理用药提供循证参考。方法:计算机检索Pubmed、Embase、Cochrane Library、Web of Science、中国生物医学文献、中国知网、万方、维普等数据库,收集关于二甲双胍对晚期非小细胞肺癌患者临床疗效影响的文献,采用Review Manager 5.3软件对结局指标总生存期(overall survival,OS)、无进展生存期(progression free survival,PFS)和客观缓解率(objective response rate,ORR)进行统计分析。结果:共纳入6篇随机对照研究和8篇队列研究,包含5030例患者。Meta分析结果显示,二甲双胍辅助治疗组的OS(HR=0.77,95%CI:0.69~0.86,P<0.0001)、PFS(HR=0.83,95%CI:0.72~0.96,P=0.01)以及ORR(RR=1.19,95%CI:1.04~1.35,P=0.008)均高于对照组。结论:二甲双胍对晚期非小细胞肺癌患者预后有积极作用,可提高患者的ORR,延长患者的PFS和OS时间。
Objective:To systematically evalute the efficacy of metformin combined with standard first-line therapy for patients with advanced non-small cell lung cancer(NSCLC),and to provide evidence-based reference for rational drug use of NSCLC.Methods:We searched databases,including Pubmed,Embase,Cochrane Library,Web of Science,CBM,CNKI,WANFANG and VIP,to collect clinical studies on the effect of metforminon combined with standard first-line therapy for patients with NSCLC.RevMan 5.3 software was used to perform the Meta-analysis.The end points included overall survival(OS),progression free survival(PFS),and objective response rate(ORR).Results:A total of 6 RCTs and 8 cohort studies were included in this study,totaling 5030 participants.According to Meta-analysis,significantly prolonged OS and PFS was found in metformin usage rather than non-metformin usage(OS:HR=0.77,95%CI:0.69~0.86,P<0.0001.PFS:HR=0.83,95%CI:0.72~0.96,P=0.01),such association was also presented in ORR(RR=1.19,95%CI:1.04~1.35,P=0.008).Conclusion:The use of metformin is positive for the prognosis of patients with advanced lung cancer.It may improve the ORR,PFS and OS time of patients.
作者
罗晓枫
陈希
王琳
蔡爽
LUO Xiaofeng;CHEN Xi;WANG Lin;CAI Shuang(Department of Pharmacy,the First Affiliated Hospital of China Medical University,Liaoning Shenyang 110001,China;College of Pharmaceutical Science,China Medical University,Liaoning Shenyang 110122,China)
出处
《现代肿瘤医学》
CAS
北大核心
2022年第11期1967-1972,共6页
Journal of Modern Oncology
基金
辽宁省科学技术计划项目(编号:2012225107)。
关键词
二甲双胍
非小细胞肺癌
预后
疗效
生存
META分析
metformin
non-small cell lung cancer(NSCLC)
prognosis
efficacy
survival
Meta-analysis
